不同化疗方案治疗晚期非小细胞肺癌成本-效果分析

目的:从药物经济学角度,观察比较TC(TAX CBP)、GP(GEM DDP)和NP(NVB DDP)联合化疗方案的合理性。方法:50例晚期肺癌患者应用3种不同化疗方案治疗,TC组18例,NP组16例,GP组16例。结果:TC组有效率44.4%、NP组有效率37.5%、GP组有效率50.0%,3组之间的近期疗效无显著差异。主要毒性为骨髓抑制和胃肠道反应。C/E分别为410.33、362.63、313.05。结论:GP组治疗晚期非小细胞肺癌成本效果比较好,毒性反应可耐受,是目前治疗NSCLC的首选方案之一。

Different Chemotherapy Regimens for Advanced Non-small Cell Lung Cancer:Cost-Effect Analysis

OBJECTIVE:To observe and compare the rationality among three combined chemotherapy regimens-TC(TAX CBP),GP(GEM DDP) and NP (NVB DDP) from the perspective of pharmacoeconomics. METHODS: Fifty patients were enrolled in this study, 18 were assigned to TC group, 16 NP group and another 16 GP group. RESULTS: The effective rates of TC, NP and GP groups were 44.4%, 37.5% and 50.0%, respectively, and the short-term therapeutic efficacies among three groups showed no statistical difference. The major toxicities wrere bone marrow suppression and gastrointestinal tract reactions. The cost-effectiveness ratios were 410.33, 362.63 and 313.05, respectively. CONCLUSION: GP is more satisfactory in curative efficacy and tolerable in its toxicity, and it is currently one of the first choices for the treatment of NSCLC.